JP6786598B2 - 抗微生物治療のための置換フェニルオキサゾリジノン - Google Patents
抗微生物治療のための置換フェニルオキサゾリジノン Download PDFInfo
- Publication number
- JP6786598B2 JP6786598B2 JP2018521488A JP2018521488A JP6786598B2 JP 6786598 B2 JP6786598 B2 JP 6786598B2 JP 2018521488 A JP2018521488 A JP 2018521488A JP 2018521488 A JP2018521488 A JP 2018521488A JP 6786598 B2 JP6786598 B2 JP 6786598B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- mmol
- alkyl
- cycloalkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *N1[C@@](CBr)CC1CBr Chemical compound *N1[C@@](CBr)CC1CBr 0.000 description 15
- GHVDTVTYZIBUJJ-LLVKDONJSA-N CNC(OC[C@@H](CN1c(cc2F)cc(F)c2N2CCSCC2)OC1=O)=O Chemical compound CNC(OC[C@@H](CN1c(cc2F)cc(F)c2N2CCSCC2)OC1=O)=O GHVDTVTYZIBUJJ-LLVKDONJSA-N 0.000 description 2
- YBUWZZKYXPWDGO-UHFFFAOYSA-N O=C1NCCSCC1 Chemical compound O=C1NCCSCC1 YBUWZZKYXPWDGO-UHFFFAOYSA-N 0.000 description 2
- OQFUNFPIPRUQAE-UHFFFAOYSA-N C1CSCCNC1 Chemical compound C1CSCCNC1 OQFUNFPIPRUQAE-UHFFFAOYSA-N 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N C1NCC11COC1 Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N C1NCCSC1 Chemical compound C1NCCSC1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- YLLQHWLPJVWHFL-SYDPRGILSA-N C1[C@@H]2N[C@H]1CSC2 Chemical compound C1[C@@H]2N[C@H]1CSC2 YLLQHWLPJVWHFL-SYDPRGILSA-N 0.000 description 1
- YAXAQXPHXNSYNQ-HNNXBMFYSA-N CC(NC[C@@H](CN1c(cc2F)ccc2N(CCC2)CCCS2=O)OC1=O)=O Chemical compound CC(NC[C@@H](CN1c(cc2F)ccc2N(CCC2)CCCS2=O)OC1=O)=O YAXAQXPHXNSYNQ-HNNXBMFYSA-N 0.000 description 1
- QUCPBUWNYUDNOL-UHFFFAOYSA-N CCCC(NCC(CN1c(cc2F)ccc2N(C(CC2)C3)C2CS3=O)OC1=O)=O Chemical compound CCCC(NCC(CN1c(cc2F)ccc2N(C(CC2)C3)C2CS3=O)OC1=O)=O QUCPBUWNYUDNOL-UHFFFAOYSA-N 0.000 description 1
- HUKVEQQWWSCOJC-LBPRGKRZSA-N COC(NC[C@@H](CN1c(cc2F)ccc2N2CC=[O]CC2)OC1=O)=O Chemical compound COC(NC[C@@H](CN1c(cc2F)ccc2N2CC=[O]CC2)OC1=O)=O HUKVEQQWWSCOJC-LBPRGKRZSA-N 0.000 description 1
- HUUPTYHXKHVJTG-NSHDSACASA-N CS(NC[C@@H](CN1c(cc2F)cc(F)c2N(CC2)CCS2=O)OC1=O)(=O)=O Chemical compound CS(NC[C@@H](CN1c(cc2F)cc(F)c2N(CC2)CCS2=O)OC1=O)(=O)=O HUUPTYHXKHVJTG-NSHDSACASA-N 0.000 description 1
- ALKWDUYZNVNYPX-NSHDSACASA-N CS(NC[C@@H](CN1c(cc2F)cc(F)c2N2CCSCC2)OC1=O)(=O)=O Chemical compound CS(NC[C@@H](CN1c(cc2F)cc(F)c2N2CCSCC2)OC1=O)(=O)=O ALKWDUYZNVNYPX-NSHDSACASA-N 0.000 description 1
- VFZCBSAHDJLPDJ-UHFFFAOYSA-N C[O]=S(CCC1)CCCN1c(ccc(N(CC(C1)(C1[n]1ncnc1)O1)C1=O)c1)c1F Chemical compound C[O]=S(CCC1)CCCN1c(ccc(N(CC(C1)(C1[n]1ncnc1)O1)C1=O)c1)c1F VFZCBSAHDJLPDJ-UHFFFAOYSA-N 0.000 description 1
- NBTTYMBZXDHFCP-UHFFFAOYSA-N Cc(cc1)ccc1S(N1CCOCC1)(=O)=O Chemical compound Cc(cc1)ccc1S(N1CCOCC1)(=O)=O NBTTYMBZXDHFCP-UHFFFAOYSA-N 0.000 description 1
- RYGUXHVSOBEPRD-HNNXBMFYSA-N N=C/N=C\NC[C@@H](CN1c(cc2)cc(F)c2N2CCCSCCC2)OC1=O Chemical compound N=C/N=C\NC[C@@H](CN1c(cc2)cc(F)c2N2CCCSCCC2)OC1=O RYGUXHVSOBEPRD-HNNXBMFYSA-N 0.000 description 1
- BVPUYCNYLMSACW-AWEZNQCLSA-N O=C(C1CC1)NC[C@@H](CN1c(cc2F)cc(F)c2N2CCSCCC2)OC1=O Chemical compound O=C(C1CC1)NC[C@@H](CN1c(cc2F)cc(F)c2N2CCSCCC2)OC1=O BVPUYCNYLMSACW-AWEZNQCLSA-N 0.000 description 1
- YZPDAWYJSNAFBT-XUJLQICISA-N O=C(C1CCC1)NC[C@@H](CN1c(cc2F)cc(F)c2N2C3CSCC2CC3)OC1=O Chemical compound O=C(C1CCC1)NC[C@@H](CN1c(cc2F)cc(F)c2N2C3CSCC2CC3)OC1=O YZPDAWYJSNAFBT-XUJLQICISA-N 0.000 description 1
- UWQQDKDYNVUOFC-QBFSEMIESA-N O=C(N(C1)c(cc2)cc(F)c2N2CCOCC2)O/C1=C\[n]1[n]ccn1 Chemical compound O=C(N(C1)c(cc2)cc(F)c2N2CCOCC2)O/C1=C\[n]1[n]ccn1 UWQQDKDYNVUOFC-QBFSEMIESA-N 0.000 description 1
- VYLQPHDPGKDBCM-ZGTMUKSFSA-N O=C(c1ccc[o]1)NC[C@@H](CN1c(cc2F)ccc2N(CCC2)CCS2=O)OC1=O Chemical compound O=C(c1ccc[o]1)NC[C@@H](CN1c(cc2F)ccc2N(CCC2)CCS2=O)OC1=O VYLQPHDPGKDBCM-ZGTMUKSFSA-N 0.000 description 1
- MVHYFUVJWYKMFM-BDPMCISCSA-N O=C(c1ccc[s]1)NC(C1)[C@@]1(CN1c(cc2F)ccc2N2CCSCCC2)OC1=O Chemical compound O=C(c1ccc[s]1)NC(C1)[C@@]1(CN1c(cc2F)ccc2N2CCSCCC2)OC1=O MVHYFUVJWYKMFM-BDPMCISCSA-N 0.000 description 1
- IFEDLORLYIKRTL-UHFFFAOYSA-N O=C1OC(C[n]2nccn2)CN1c(cc1)cc(F)c1N1CCSCC1 Chemical compound O=C1OC(C[n]2nccn2)CN1c(cc1)cc(F)c1N1CCSCC1 IFEDLORLYIKRTL-UHFFFAOYSA-N 0.000 description 1
- WJRFQYHAFLFMRD-HNNXBMFYSA-N O=C1O[C@@H](C[n]2ncnc2)CN1c(cc1F)ccc1N1CCCSCCC1 Chemical compound O=C1O[C@@H](C[n]2ncnc2)CN1c(cc1F)ccc1N1CCCSCCC1 WJRFQYHAFLFMRD-HNNXBMFYSA-N 0.000 description 1
- AJUSRSPIZPVPOE-YIZWMMSDSA-N O=C1O[C@@H](C[n]2nncc2)CN1c(cc1F)cc(F)c1N1C2CSCC1CC2 Chemical compound O=C1O[C@@H](C[n]2nncc2)CN1c(cc1F)cc(F)c1N1C2CSCC1CC2 AJUSRSPIZPVPOE-YIZWMMSDSA-N 0.000 description 1
- VDWRWMLZEWMDPD-BERXXLLYSA-N O=C1O[C@@H](C[n]2nncc2)CN1c(cc1F)ccc1N(C(CC1)C2)C1CS2=O Chemical compound O=C1O[C@@H](C[n]2nncc2)CN1c(cc1F)ccc1N(C(CC1)C2)C1CS2=O VDWRWMLZEWMDPD-BERXXLLYSA-N 0.000 description 1
- VLGMZORUTDNYJC-GLXQMMQGSA-N OC(C1)[C@@]1(C1)N(Cc2ccccc2)[C@H]1O Chemical compound OC(C1)[C@@]1(C1)N(Cc2ccccc2)[C@H]1O VLGMZORUTDNYJC-GLXQMMQGSA-N 0.000 description 1
- TWJNNXKBAKEEIH-UHFFFAOYSA-N OC1OC(CNC(C2CC2)=O)CN1c(cc1F)ccc1N1CCOCC1 Chemical compound OC1OC(CNC(C2CC2)=O)CN1c(cc1F)ccc1N1CCOCC1 TWJNNXKBAKEEIH-UHFFFAOYSA-N 0.000 description 1
- QEJPOEGPNIVDMK-UHFFFAOYSA-N OCC(CBr)(CBr)CBr Chemical compound OCC(CBr)(CBr)CBr QEJPOEGPNIVDMK-UHFFFAOYSA-N 0.000 description 1
- XWSBAVVPGULZOY-UHFFFAOYSA-N ON=C1CCSCC1 Chemical compound ON=C1CCSCC1 XWSBAVVPGULZOY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193963P | 2015-07-17 | 2015-07-17 | |
| US62/193,963 | 2015-07-17 | ||
| PCT/US2016/042486 WO2017015106A1 (en) | 2015-07-17 | 2016-07-15 | Substituted phenyloxazolidinones for antimicrobial therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086709A Division JP7232212B2 (ja) | 2015-07-17 | 2020-05-18 | 抗微生物治療のための置換フェニルオキサゾリジノン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524406A JP2018524406A (ja) | 2018-08-30 |
| JP2018524406A5 JP2018524406A5 (enExample) | 2019-06-13 |
| JP6786598B2 true JP6786598B2 (ja) | 2020-11-18 |
Family
ID=57834866
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521488A Active JP6786598B2 (ja) | 2015-07-17 | 2016-07-15 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2020086709A Active JP7232212B2 (ja) | 2015-07-17 | 2020-05-18 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2021143166A Withdrawn JP2021183647A (ja) | 2015-07-17 | 2021-09-02 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2023127905A Active JP7585405B2 (ja) | 2015-07-17 | 2023-08-04 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2024140841A Pending JP2024152930A (ja) | 2015-07-17 | 2024-08-22 | 抗微生物治療のための置換フェニルオキサゾリジノン |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086709A Active JP7232212B2 (ja) | 2015-07-17 | 2020-05-18 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2021143166A Withdrawn JP2021183647A (ja) | 2015-07-17 | 2021-09-02 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2023127905A Active JP7585405B2 (ja) | 2015-07-17 | 2023-08-04 | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2024140841A Pending JP2024152930A (ja) | 2015-07-17 | 2024-08-22 | 抗微生物治療のための置換フェニルオキサゾリジノン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10550092B2 (enExample) |
| EP (2) | EP3932917A3 (enExample) |
| JP (5) | JP6786598B2 (enExample) |
| KR (1) | KR102511898B1 (enExample) |
| CN (2) | CN108348507B (enExample) |
| AU (3) | AU2016295165B2 (enExample) |
| BR (1) | BR112018000991A2 (enExample) |
| CA (1) | CA2990260A1 (enExample) |
| EA (2) | EA202190167A1 (enExample) |
| ES (1) | ES2897973T3 (enExample) |
| WO (1) | WO2017015106A1 (enExample) |
| ZA (1) | ZA201800189B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021183647A (ja) * | 2015-07-17 | 2021-12-02 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | 抗微生物治療のための置換フェニルオキサゾリジノン |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066964A1 (en) * | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
| CN108727406B (zh) * | 2017-03-28 | 2021-12-07 | 北京协和制药二厂 | 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 |
| US12109203B2 (en) | 2018-07-25 | 2024-10-08 | Zydus Lifesciences Limited | Substituted oxazolidinones for the treatment of mammalian infections |
| WO2020147504A1 (en) * | 2019-01-18 | 2020-07-23 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
| WO2020234636A1 (en) | 2019-05-17 | 2020-11-26 | Cadila Healthcare Limited | Novel compounds for the treatment of mammalian infections |
| CN110922411B (zh) * | 2019-11-27 | 2021-06-04 | 合肥远志医药科技开发有限公司 | 一种药物中间体的合成方法 |
| WO2021184339A1 (en) * | 2020-03-20 | 2021-09-23 | Merck Sharp & Dohme Corp. | Oxazolidinone compound and methods of use thereof as an antibacterial agent |
| CN113999152B (zh) * | 2021-07-14 | 2023-05-09 | 上海凌富药物研究有限公司 | 一种顺式-1-苄基-2,4-二烷氧基羰基氮杂环丁烷的合成方法 |
| WO2024035618A1 (en) * | 2022-08-10 | 2024-02-15 | Merck Sharp & Dohme Llc | Processes for preparing oxazolidinone compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) * | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT792273E (pt) * | 1994-11-15 | 2003-06-30 | Upjohn Co | Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas |
| DE69614847T2 (de) * | 1995-05-11 | 2002-04-04 | Pharmacia & Upjohn Co., Kalamazoo | Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone |
| US6255304B1 (en) * | 1997-05-30 | 2001-07-03 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
| JP2002531455A (ja) * | 1998-11-27 | 2002-09-24 | ファルマシア・アンド・アップジョン・カンパニー | チオカルボニル官能基を有するオキサゾリジノン抗細菌剤 |
| MXPA04000357A (es) * | 2001-07-12 | 2004-05-04 | Pharmacia & Up John Company | COMPUESTO QUE CONTIENE AMIDA Y TIENE UNA MEJOR SOLUBILIDAD, Y MeTODO PARA MEJORAR LA SOLUBILIDAD DE UN COMPUESTO QUE CONTIENE AMIDA. |
| MXPA04008312A (es) | 2002-02-28 | 2004-11-26 | Astrazeneca Ab | Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos. |
| AU2003224345A1 (en) * | 2002-04-30 | 2003-11-17 | Orchid Chemicals & Pharmaceuticals | Antibacterial agents |
| TW200403240A (en) * | 2002-06-28 | 2004-03-01 | Upjohn Co | Difluorothioacetamides of oxazolidinones as antibacterial agents |
| US6875784B2 (en) * | 2002-10-09 | 2005-04-05 | Pharmacia & Upjohn Company | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives |
| CN1237056C (zh) * | 2002-12-25 | 2006-01-18 | 中国科学院上海药物研究所 | 噁唑烷酮类化合物、其制备方法和用途 |
| JP2007503426A (ja) * | 2003-08-25 | 2007-02-22 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 新規な抗微生物性アリールオキサゾリジノン化合物 |
| JP2008521790A (ja) * | 2004-11-29 | 2008-06-26 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌剤としてのチアゼピンオキサゾリジノン |
| US7332611B2 (en) * | 2005-05-06 | 2008-02-19 | University Of South Florida | N-thiolated 2 oxazolidone antibiotics |
| JP2008544979A (ja) * | 2005-06-29 | 2008-12-11 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌剤としてのホモモルホリンオキサゾリジノン |
| CA2614105A1 (en) * | 2005-07-06 | 2007-01-11 | Pharmacia & Upjohn Company Llc | Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents |
| NZ587096A (en) * | 2008-03-26 | 2011-11-25 | Global Alliance For Tb Drug Dev | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
| KR100980681B1 (ko) * | 2008-09-16 | 2010-09-07 | 한국과학기술연구원 | 디플루오로페닐 유도체를 갖는 신규한 옥사졸리디논 유도체또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 하는 항생제 조성물 |
| US20110053916A1 (en) * | 2009-08-14 | 2011-03-03 | Vertex Pharmaceuticals Incorporated | Pyrimidine compounds as tuberculosis inhibitors |
| AU2016295165B2 (en) * | 2015-07-17 | 2021-04-22 | The Global Alliance For Tb Drug Development, Inc. | Substituted phenyloxazolidinones for antimicrobial therapy |
| JP2023127905A (ja) * | 2022-03-02 | 2023-09-14 | パナソニックＩｐマネジメント株式会社 | 物品管理システム、物品管理方法及びプログラム |
-
2016
- 2016-07-15 AU AU2016295165A patent/AU2016295165B2/en active Active
- 2016-07-15 ES ES16828300T patent/ES2897973T3/es active Active
- 2016-07-15 CA CA2990260A patent/CA2990260A1/en active Pending
- 2016-07-15 EA EA202190167A patent/EA202190167A1/ru unknown
- 2016-07-15 EP EP21185896.4A patent/EP3932917A3/en active Pending
- 2016-07-15 EP EP16828300.0A patent/EP3307268B1/en active Active
- 2016-07-15 US US15/738,503 patent/US10550092B2/en active Active
- 2016-07-15 CN CN201680054227.1A patent/CN108348507B/zh active Active
- 2016-07-15 KR KR1020187003093A patent/KR102511898B1/ko active Active
- 2016-07-15 EA EA201792566A patent/EA037643B1/ru unknown
- 2016-07-15 CN CN202111073361.5A patent/CN113603683B/zh active Active
- 2016-07-15 WO PCT/US2016/042486 patent/WO2017015106A1/en not_active Ceased
- 2016-07-15 BR BR112018000991A patent/BR112018000991A2/pt not_active Application Discontinuation
- 2016-07-15 JP JP2018521488A patent/JP6786598B2/ja active Active
-
2018
- 2018-01-10 ZA ZA2018/00189A patent/ZA201800189B/en unknown
-
2020
- 2020-01-13 US US16/740,660 patent/US11964949B2/en active Active
- 2020-05-18 JP JP2020086709A patent/JP7232212B2/ja active Active
-
2021
- 2021-07-16 AU AU2021205116A patent/AU2021205116B2/en active Active
- 2021-09-02 JP JP2021143166A patent/JP2021183647A/ja not_active Withdrawn
-
2022
- 2022-11-11 AU AU2022268387A patent/AU2022268387A1/en not_active Abandoned
-
2023
- 2023-08-04 JP JP2023127905A patent/JP7585405B2/ja active Active
-
2024
- 2024-08-22 JP JP2024140841A patent/JP2024152930A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021183647A (ja) * | 2015-07-17 | 2021-12-02 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP2023133610A (ja) * | 2015-07-17 | 2023-09-22 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | 抗微生物治療のための置換フェニルオキサゾリジノン |
| JP7585405B2 (ja) | 2015-07-17 | 2024-11-18 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | 抗微生物治療のための置換フェニルオキサゾリジノン |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7585405B2 (ja) | 抗微生物治療のための置換フェニルオキサゾリジノン | |
| AU2018306606B2 (en) | Compounds and methods for the targeted degradation of Androgen Receptor | |
| AU2023285742A1 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| KR20090130347A (ko) | 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도 | |
| HK40062709A (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
| HK40062709B (zh) | 用於抗微生物治疗的经取代苯基恶唑烷酮 | |
| US12109203B2 (en) | Substituted oxazolidinones for the treatment of mammalian infections | |
| HK1255105B (zh) | 用於抗微生物治疗的经取代苯基恶唑烷酮 | |
| NZ738702B2 (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
| CA3012443A1 (en) | Substituted 2-phenyl-2,3-dihydro-1h-inden-2-yl-propionamides as mglur7 modulators | |
| RU2798336C2 (ru) | Новые соединения для лечения инфекций млекопитающих | |
| EA043707B1 (ru) | Замещенные фенилоксазолидиноны для антимикробной терапии | |
| WO2025109540A1 (en) | Macrocyclic compounds as kif18a inhibitors | |
| HK40043248A (en) | Substituted oxazolidinones for the treatment of mammalian infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190509 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190509 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200518 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201027 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201028 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6786598 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |